QPS Clinical Phase I/IIa Development Services
Moving quickly and safely through Phase I/IIa trials is critical to successful drug development. The QPS Phase I research facilities feature more than 550 beds across six strategically located facilities on three continents. QPS is well known for its success in first-in-human clinical trials. All Phase I sites are staffed by expert clinical pharmacology teams that routinely conduct hundreds of phase I/IIa studies annually.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Moving quickly and safely through Phase I/IIa trials is critical to successful drug development.
The QPS Phase I/IIa research facilities feature more than 550 beds across six strategically located facilities on three continents. QPS is well known for its success in first-in-human clinical trials. All Phase I sites are staffed by expert clinical pharmacology teams that routinely conduct hundreds of phase I/IIa studies annually.
We also have scientific expertise in the design of all types of Phase I studies (formerly referred to as “first-in-man” studies), including dose response, SAD, and MAD studies, as well as the interpretation of study data.
We specialize in conducting proof-of-concept (POC) studies in special and patient populations. Our proof-of-concept studies help ensure a study’s safety and value and prevent resources from being wasted on targets and molecules that aren’t likely to succeed. When well designed and properly conducted, proof-of-concept studies establish the basis for large-scale dose response, efficacy, and safety studies that will assess efficacy, tolerability, side effects, and associated risks.
QPS Global Phase I Facilities:
- 58 beds in Groningen, the Netherlands
- 138 beds in Hyderabad, India
- 8 beds in Leeuwarden, the Netherlands
- 95 beds in South Miami, Florida, USA
- 240 beds in Springfield, Missouri, USA
- 40 beds in Taipei, Taiwan
A flexible approach to early phase clinical trials
In this application note, QPS describes how, with six phase I sites on three continents, it offers comprehensive services including small scale complex studies, high-capacity studies in healthy volunteers, and Proof of Concept studies in patient or specialty populations, for a wide variety of therapeutic indications.
Five criteria to use when selecting a CRO for a gene therapy study
With cell and gene therapies (CGT) quickly making their way from theory to clinical practice, many biopharmaceutical companies are looking for CRO partners with significant experience conducting CGT-focused clinical studies. In this white paper, QPS describes five criteria to consider when evaluating organizations.
Human AME (mass balance) studies
In this white paper, QPS describes human AME (hAME) studies and the complexities of carrying out these trials, particularly with respect to managing and conducting radiolabelled hAME.
Selecting the location of a phase I clinical trial site for EU registration
In this white paper, QPS provides insight into conducting trials that will support registration of a medicinal product in the EU. In such cases, regional authorities establish trial requirements as set forth in the marketing authorization application (MAA).
Pharmacokinetic studies in patients
In this white paper, QPS describes why there is both a scientific and an ethical imperative to ensure PK studies are designed such that they provide useable results.
Excellence in complex clinical trials
In this video, discover case studies highlighting the importance of successful partnerships when conducting complex clinical studies. The video covers case studies including biomarker-driven bone marrow assessments, full sedation studies, and lipopolysaccharide (LPS) challenges.
